z-logo
Premium
UPLC–MS/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units
Author(s) -
ElNajjar Nahed,
Hösl Julian,
Holzmann Thomas,
Jantsch Jonathan,
Gessner André
Publication year - 2018
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.2253
Subject(s) - cefepime , meropenem , piperacillin , therapeutic drug monitoring , ampicillin , chromatography , ceftazidime , trimethoprim , chemistry , antibiotics , ertapenem , protein precipitation , pharmacokinetics , imipenem , pharmacology , medicine , high performance liquid chromatography , biochemistry , antibiotic resistance , biology , bacteria , pseudomonas aeruginosa , genetics
A large variation in the levels of different ß‐lactams and other antibiotics used in critically ill patients has been documented. The aim of this study is to establish and validate a fast, ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) method for the simultaneous analysis of ten antibiotics (Meropenem, Cefepime, Ceftazidime, Piperacillin, Benzylpenicillin, Ampicillin, Flucloxacillin, Linezolid, and Sulfamethoxazole/Trimethoprim) in human plasma according to European Medicines Agency (EMA) guidelines. Protein precipitation with ice‐cold methanol containing 9 isotopically labeled internal standards was used for sample clean up. Antibiotics were detected, following a 4‐minute gradient separation, in multiple reactions monitoring (MRM) using API 4000 instrument equipped with electrospray source operating in positive ion mode. The lower limit of quantification was 0.1 mg/L for Meropenem, Ceftazidime, Piperacillin, Ampicillin, Flucloxacillin, and Sulfamethoxazole; 0.05 mg/L for Cefepime, Benzylpenicillin, and Trimethoprim; and 0.02 mg/L for Linezolid. The method proved to be precise and accurate and applicable for therapeutic drug monitoring and other pharmacokinetic studies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here